Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Kisunla 350 mg concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
donanemab
Company:  
Eli Lilly and Company Limited See contact details
ATC code: 
N06DX05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Live Chat
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Kisunla®▼(donanemab) A Guide for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

HCP education guide.

{pdf_link}

Kisunla®▼(donanemab) Patient Alert Card

patient alert card

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Eli Lilly and Company Limited
Company image
Address
Lilly House, Basing View, Basingstoke, Hampshire, RG21 4FA
Telephone
+44 (0)1256 315 000
WWW
https://www.lilly.com/uk/
Medical Information e-mail
[email protected]
Medical Information Website
https://www.lillymedical.co.uk/en-gb